A Pilot Study of 0.4% Povidone-Iodine Nasal Spray to Eradicate SARS-CoV-2 in the Nasopharynx

Figures & data

Table 1 Demographic Data of 12 Patients with Culturable NP Samples

ID	Age Range (Years)	Sex	BMI (kg/m^2)	Disease Severity	Duration from Symptom Onset to Enrollment (Days)	TCID50/mL (Baseline, Left Side of Nasopharynx)
1	51–55	F	20.7	Mild	3	640
2	26–30	F	25.1	Mild	3	640
3	21–25	M	23.5	Mild	2	40,960
4	46–50	M	19.7	Mild	4	2560
5	41–45	M	22.7	Asymptomatic	NA	10,240
6	41–45	F	20.1	Mild	1	10,240
7	41–45	M	23.5	Asymptomatic	NA	640
8	26–30	F	27.3	Mild	1	2560
9	21–25	M	24.0	Mild	4	10,240
10	31–35	M	26.0	Asymptomatic	NA	5120
11	26–30	F	26.4	Mild	3	40,960
12	36–40	F	41.4	Mild	4	640

Abbreviations: ID, identification number; F, female; M, male; NA, not applicable;TCID₅₀, median tissue culture infectious dose; NP, nasopharyngeal.

Figure 1 CONSORT flow diagram of the pilot study.

Note: Adapted from Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med. 2010;7(3): e1000251. Copyright: © 2010 Schulz et al. Creative Commons Attribution License.²⁰

Table 2 Cycle Threshold (Ct) Values for Culturable NP Samples

ID	N (Baseline, Lt)	ORF1ab (Baseline, Lt)	N (3 min, Lt)	ORF1ab (3 min, Lt)	N (3 min, Rt)	ORF1ab (3 min, Rt)	N (4 h, Rt)	ORF1ab (4 h, Rt)
1	21.96	23.00	25.42	26.52	23.44	24.61	21.93	22.91
2	22.64	24.18	23.99	25.45	20.71	22.34	24.47	26.12
3	19.71	21.31	21.54	23.13	19.32	20.62	20.41	21.68
4	20.73	20.14	20.18	21.47	19.79	21.16	19.96	21.29
5	17.73	19.00	18.54	19.83	19.74	21.09	22.23	23.49
6	18.45	19.53	19.23	18.08	18.69	19.87	18.20	19.32
7	20.40	22.52	23.62	26.22	21.49	23.63	21.27	23.10
8	19.96	18.46	19.10	17.72	17.03	15.72	18.21	16.91
9	16.19	15.08	16.42	15.17	17.36	16.29	17.94	16.61
10	17.89	16.27	16.39	15.07	15.73	14.50	16.76	15.39
11	16.30	15.20	15.40	14.36	19.41	18.23	16.91	15.83
12	21.78	20.38	19.75	18.51	24.40	23.30	24.68	23.47

Abbreviations: ID, identification number; Lt, left nasopharyngeal samples; Rt, right nasopharyngeal samples; NP, nasopharyngeal.

Table 3 Viral Titers for Culturable NP Samples

ID	TCID50/mL (Baseline, Lt.)	TCID50/mL (3 min, Lt.)	TCID50/mL (3 min, Rt.)	TCID50/mL (4 h, Rt.)
1	640	10	80	160
2	640	40	160	10
3	40,960	2560	10,240	10,240
4	2560	40,960	320	640
5	10,240	5120	320	160
6	10,240	1280	10,240	1280
7	640	160	40	320
8	2560	2560	640	640
9	10,240	40,960	640	5120
10	5120	40,960	40,960	40,960
11	40,960	10,240	2560	20,480
12	640	40	0	0

Abbreviations: ID, identification number; Lt, left nasopharyngeal samples; Rt, right nasopharyngeal samples; NP, nasopharyngeal.

Table 4 Change in Viral Titers After 3 Minutes and 4 Hours Exposure to PVP-I as Compared to the Baseline Value from Left NP Specimens

ID	≈ 10-Fold Reduction	Within 4 Fold Reduction	No Change or Increase
1	3 min, Lt.	3 min, Rt.; 4h, Rt.	0
2	4h, Rt.	3 min, Lt.; 3 min, Rt.	0
3	0	3 min, Lt.; 3 min, Rt.; 4h, Rt.	0
4	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
5	0	3 min, Lt.; 3 min, Lt; 4h, Rt.	0
6	0	3 min, Lt.; 4h, Rt.	3 min, Lt.
7	3 min Rt.	3 min, Lt.;4h, Rt.
8	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
9	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
10	0	0	3 min, Lt.; 3 min, Lt.; 4h, Rt.
11	3 min, Rt.	3 min, Lt; 4h, Rt.	0
12	3 min, Lt.; 3 min, Rt.; 4h, Rt.	0	0
Total specimens	7	22	7

Abbreviations: ID, identification number; Lt, left nasopharyngeal samples; Rt, right nasopharyngeal samples; NP, nasopharyngeal.

Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med. 2010;7(3): e1000251. Copyright: © 2010 Schulz et al. Creative Commons Attribution License.

 Google Scholar